Table 3.
Summary of noncovalent-binding LSD1/KDM1A inhibitors.
| Compound name | LSD1 inhibition (nM) | PDB ID | Resolution (Å) | Reference |
|---|---|---|---|---|
| Polyamine analogues | ||||
| Verlindamycin | 13,000b | 106,107 | ||
| Bisthiourea “6d" | 4,800b | 107 | ||
| Small-molecule inhibitors | ||||
| CBB1007 | 5,270b | 108 | ||
| Namoline | 51,000b | 109 | ||
| Amidoxin “22" | 16,800b | 110 | ||
| Phenyl oxazole “9a" | 9,500b | 111 | ||
| Aminothiazole “16k" | 7,500b | 112 | ||
| SP2509/HCI2509 | 13b | 120 | ||
| Benzohydrazide “5a” (10) | 1.4b | 123 | ||
| GSK354/GSK690 | 90b | 119d | ||
| Pyridine containing “17” (11) | 29a | 96 | ||
| XZ09 | 2,410b | 116 | ||
| Pyrimidine-thiourea “6b" | 650b | 117 | ||
| Triazole-based “26" | 2,100b | 113 | ||
| Triazole-based “8k" | 390b | 114 | ||
| Triazole-based “6" | 1,192b | 115 | ||
| Triazole-based “5p” (12) | 154b | 118 | ||
| E11 (14) | 440a | 5L3E | 2.8 | 126 |
| MC3767 | not determineda | 5LBQ | 3.3 | 126 |
| Natural products | ||||
| Resveratrol | 15,000b | 128 | ||
| Geranylgeranoic acid | 22,220b | 129 | ||
| Polymixin B (13) | 157a | 5L3F | 3.5 | 126 |
| Polymixin E | 193a | 5L3G | 3.1 | 126 |
| Baicalin | 3,010b | 130 | ||
| Peptidic inhibitors | ||||
| H3K4M (1–21) | 40a, 50a | 2V1D | 3.1 | 32 |
| SNAIL peptide (1–20) | 210a | 2Y48 | 3.0 | 46 |
| SNAIL peptide PRSFLV | 28,400a | 3ZMTc | 3.1 | 132 |
a
Ki;
b
IC50;
c
Related structures: 3ZMS, 3ZMU, 3ZMV, 3ZMZ, 3ZN0, 3ZN1;
d
Review.